What is Syncardia Systems?
Syncardia Systems, based in Tucson, Arizona, is the sole manufacturer of the FDA, Health Canada, and CE-approved Total Artificial Heart. This life-saving device serves as a crucial bridge to transplant for individuals suffering from biventricular end-stage heart failure, enabling them to survive until a donor heart becomes available. Beyond the artificial heart, the company also produces the Freedom portable driver, which empowers clinically stable patients to leave the hospital and await transplantation in the comfort of their homes. The company's focus on this niche yet vital segment of cardiovascular care positions it as a key player in the medical technology landscape.
How much funding has Syncardia Systems raised?
Syncardia Systems has raised a total of $42.3M across 7 funding rounds:
Series B
$3.7M
Series D
$10.3M
Private Equity
$5M
Debt
$14M
Private Equity
$6.4M
Debt
$1M
Debt
$1.9M
Series B (2004): $3.7M, investors not publicly disclosed
Series D (2009): $10.3M led by Highway 12 Ventures
Private Equity (2011): $5M, investors not publicly disclosed
Debt (2013): $14M featuring SWK Holdings and Athyrium Capital Management
Private Equity (2014): $6.4M, investors not publicly disclosed
Debt (2020): $1M with participation from PPP
Debt (2021): $1.9M led by PPP
Key Investors in Syncardia Systems
Highway 12 Ventures
Highway 12 Ventures is a venture capital firm that has participated in Syncardia Systems' funding rounds. Their investment suggests a focus on companies with significant growth potential in specialized sectors.
SWK Holdings
SWK Holdings, a life science specialty finance company, has provided capital to Syncardia Systems. Their involvement indicates a strategic approach to financing within the healthcare industry, likely supporting the company's operational and developmental needs.
Athyrium Capital Management
Athyrium Capital Management, a firm specializing in structured investments within the global healthcare sector, has backed Syncardia Systems. Their expertise in financing diverse healthcare companies suggests a strategic alignment with Syncardia's mission.
What's next for Syncardia Systems?
The recent major strategic investment in Syncardia Systems signals a period of potential expansion and further development for the company. With a history of securing substantial capital, including significant debt and private equity rounds, Syncardia Systems is well-positioned to advance its technology, scale its manufacturing capabilities, and potentially broaden its market reach. Future growth may involve enhancing the portability and functionality of its artificial heart systems, exploring new therapeutic applications, or forging strategic partnerships to accelerate patient access to its life-saving devices. The company's ongoing commitment to innovation in the critical field of heart failure treatment is likely to attract continued investor interest.
See full Syncardia Systems company page
